普通外文研报
Vizionfocus Inc (4771 TT, NT$186.50) - Ramp-up to keep up with customer orders on robust demand
研报英文原文证据摘录
Vizionfocus Inc (4771 TT, NT$186.50) - Ramp-up to keep up with customer orders on robust demand
Taiwan Equity | Biotechnology
Company Snapshot
Fubon Research Vizionfocus Inc (4771 TT)
May 19, 2026
_ Ramp-up to keep up with customer orders on robust demand
Buy
Reiterate Buy, target price of NT$232, 24% upside
Price Target price
NT$186.50 NT$232 1. Robust demand from Japan and China, 1Q26 EPS beat
○Visit notes ○Initiating coverage 2. Double-digit growth expected in China, Japan, Taiwan in FY26
●Company update ●Earnings revision 3. Strong order momentum, continued capacity expansion to drive double-digit profit
○Earnings preview ○Rating change
growth
Shares out. (mn) 59
Mkt cap (NT$mn) 10,980
Mkt cap (US$mn) 348 Robust demand from Japan, China, 1Q26 EPS beat
FINI holding (%) 5.34 1Q26 sales reached NT$1.03bn, up 27.2% YoY and 8.4% QoQ, as its operations benefited
Local IM holding (%) 0.00 from continued order momentum from Japan and China, driving utilization rates at both
Directors holding (%) 21.34
Taiwan and China plants to over 95%. GM was slightly down QoQ by 0.3ppt to 41% due
52-week high (NT$) 207.40
52-week low (NT$) 170.00 to forex. As for opex, its subsidiary expanded its retail presence in Taiwan by entering
Day-trading % 24% major chain channels such as Poya, Cosmed, and Watsons, up 27% YoY to NT$124mn, in
line with Fubon’s expectations. Overall, supported by high utilization rates, OpM was
ESG rating 4 Industry Rank 102/154 28.9% and net EPS was NT$3.66, up 10% YoY, slightly better than our forecast of NT$3.62.
Double-digit growth expected in China, Japan, Taiwan in FY26
Growth momentum in FY26 will mainly come from the China and Japan markets, and we
maintain our previous regional forecasts: 1) China accounts for 50%. Leveraging its high
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器